Roche Holding AG
SIX:ROG
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
CH |
Roche Holding AG
SIX:ROG
|
176.2B CHF | 4.4 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -164 697 976 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 26.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 20.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 1 026 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 446.1 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 6.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 8.1 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 53.2 | ||
CH |
Novartis AG
SIX:NOVN
|
182.9B CHF | 6 | ||
US |
Pfizer Inc
NYSE:PFE
|
143.4B USD | 4.9 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.